Helismith said HX106, its adjuvant therapy for treating impulsive behavior, has proven efficacy in treating attention deficit hyperactivity disorder (ADHD), especially when used together with methylphenidate.

Its research team conducted clinical trials by administering HX106 on two groups of 29 ADHD patients taking methylphenidate. The first group took methylphenidate and placebo, and the latter took HX106 for four weeks with methylphenidate. The result showed the group with HX106 injections improved on concentration, as indicated by the K-ARS, the Korean version of the DuPaul ADHD Rating Scale. 

HX106 is a plant complex extract developed by the natural product team at the company, which received the Ministry of Food and Drug Safety’s approval as individual raw material for improving working memory in 2015, the company said in a news release Tuesday.

 “The brain functional magnetic resonance imaging analysis showed groups who took HX106 improved activation and connectivity of the brain regions, which control the attention,” said Lee Doo-suk,  a senior researcher at Helixmith. “The finding is significant because while ADHD treatments may have side effects, HX106 is made with safe and natural ingredients.” 

Helixmith President Yu Seung-shin also said, “We will continue to develop products to improve brain health, based on our proven efficacy of HX106.”

The clinical trial results were published in Integrative Medicine Research.